EICHOR
● Completed
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Condition: Metastatic Renal Cell Carcinoma (mRCC) · Sponsor: Pfizer
About this study
This is an international, multi-centre, prospective (partly retrospective), observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated with sunitinib in first line and/or receiving axitinib in second line post sunitinib. The study is designed to enroll approximately 750 patients over the course of an enrollment period of approximately 36 months.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (110)
| Landeskrankenhaus Bregenz | Bregenz, Austria | — |
| AKh Linz | Linz, Austria | — |
| Krankenhaus der Barmherzigen Schwestern Linz Abteilung fuer Urologie | Linz, Austria | — |
| Krankenhaus Oberwart | Oberwart, Austria | — |
| Universitasklinik für Urologie und Andrologie | Salzburg, Austria | — |
| AKH - Universitaetsklinik fuer Innere Medizin I | Vienna, Austria | — |
| AKH-Universitat Klinik fur Innere Medizin I | Vienna, Austria | — |
| Sozialmedizinisches Zentrum Ost | Vienna, Austria | — |
| ASZ Aalst - Campus Aalst | Aalst, Belgium | — |
| Imeldaziekenhuis | Bonheiden, Belgium | — |
| Algemeen Ziekenhuis Sint-Lucas, Dienst Oncologie | Ghent, Belgium | — |
| AZ Maria Middelares | Ghent, Belgium | — |
+ 98 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02184416